retatrutide mechanism trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Frontiers | Mechanisms of action

Noonly your prescribing physician can modify dosages

The synthetic peptide is a triple hormone receptor, engineered not only to activate the bodys GLP1 receptors but also two other receptors (glucose-dependent insulinotropic polypeptide and glucagon) involved in controlling insulin secretion, glucose uptake and energy expenditure, as well as decreasing gastric emptying and appetite

Embarking on a weight loss journey with a GLP-1 medication is a powerful step toward improving your health, but managing your body composition is vital to ensuring that journey is both safe and successful

Patients with poorly controlled diabetes, cardiovascular risk, obesity-related comorbidities, and those facing access barriers should be prioritized

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity

Keats, E